DaVita Inc. (NYSE:DVA) Receives $199.17 Consensus Target Price from Brokerages

DaVita Inc. (NYSE:DVA) has received a consensus rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $199.1667.

Several brokerages recently weighed in on DVA. UBS Group lifted their price target on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Truist Financial lifted their price target on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. TD Cowen lifted their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Barclays lifted their price target on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Finally, Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and lifted their price target for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th.

DaVita Stock Down 0.4%

Shares of NYSE:DVA opened at $208.91 on Wednesday. DaVita has a 52-week low of $101.00 and a 52-week high of $211.95. The stock has a market cap of $13.41 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 0.69 and a beta of 0.91. The business has a 50-day moving average price of $178.66 and a 200-day moving average price of $147.52.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.DaVita’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the business earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts anticipate that DaVita will post 15.07 EPS for the current fiscal year.

Insider Activity at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is owned by company insiders.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently made changes to their positions in the business. Todd Asset Management LLC purchased a new stake in shares of DaVita in the third quarter valued at approximately $21,842,000. Doma Perpetual Capital Management LLC boosted its stake in shares of DaVita by 23.3% in the third quarter. Doma Perpetual Capital Management LLC now owns 355,574 shares of the company’s stock worth $47,245,000 after acquiring an additional 67,214 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of DaVita by 122.4% in the third quarter. Intech Investment Management LLC now owns 27,441 shares of the company’s stock worth $3,646,000 after acquiring an additional 15,104 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of DaVita by 18.0% in the fourth quarter. Nordea Investment Management AB now owns 338,192 shares of the company’s stock worth $38,321,000 after acquiring an additional 51,607 shares during the last quarter. Finally, Munich Reinsurance Co Stock Corp in Munich acquired a new stake in shares of DaVita in the third quarter worth approximately $5,419,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.